LONG-TERM OUTCOME FOLLOWING TOTAL PARATHYROIDECTOMY IN PATIENTS WITH END-STAGE RENAL-DISEASE

被引:2
|
作者
KAYE, M
ROSENTHALL, L
HILL, RO
TABAH, RJ
机构
[1] MONTREAL GEN HOSP,DEPT NUCL MED,MONTREAL H3G 1A4,QUEBEC,CANADA
[2] MONTREAL GEN HOSP,DEPT DIAGNOST RADIOL,MONTREAL H3G 1A4,QUEBEC,CANADA
[3] MONTREAL GEN HOSP,DEPT SURG,MONTREAL H3G 1A4,QUEBEC,CANADA
关键词
PARATHYROIDECTOMY; DIALYSIS; END-STAGE RENAL DISEASE;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Long-term follow up (mean 3.8 years), following elective total parathyroidectomy in thirteen patients with end-stage renal disease is described. Nine patients are alive and all except two have measurable levels of intact parathyroid hormone (PTH). One patient is mildly hyperparathyroid with PTH levels of 143 pg/ml (normal 10-65 pg/ml). All patients did well as far as their bone and mineral metabolism were concerned and there were no fractures, bone pain or metastatic soft tissue calcification. Lumbar spine bone mineral density (BMD) increased above the baseline value and femoral neck bone density was significantly greater than a matched control group of non-parathyroidectomized dialysis patients (1.097 +/- 0.140 versus 0.811 +/- 0.148 g/cm2, Z-score 1.98 +/- 1.64 versus -0.79 +/- 1.07, p <0.001). Two of the nine patients have been transplanted, both have good allograft function and show increases in BMD. We believe that these findings justify the complete removal of all parathyroid tissue for selected patients with chronic renal failure where medical therapy has failed and aluminium bone disease has been excluded. They also raise the possibility that PTH is necessary for bone loss to occur.
引用
收藏
页码:192 / 197
页数:6
相关论文
共 50 条
  • [31] THE ROLE OF SUPPORT IN INFLUENCING OUTCOME OF END-STAGE RENAL-DISEASE
    BURTON, HJ
    KLINE, SA
    LINDSAY, RM
    HEIDENHEIM, P
    GENERAL HOSPITAL PSYCHIATRY, 1988, 10 (04) : 260 - 266
  • [32] Long-term outcomes of children with end-stage renal disease
    Groothoff, JW
    PEDIATRIC NEPHROLOGY, 2005, 20 (07) : 849 - 853
  • [33] PHARMACODYNAMICS OF ZIDOVUDINE IN PATIENTS WITH END-STAGE RENAL-DISEASE
    PAOLI, I
    DAVE, M
    COHEN, BD
    NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (12): : 839 - 840
  • [34] CARDIAC OPERATIONS IN PATIENTS WITH END-STAGE RENAL-DISEASE
    KAUL, TK
    FIELDS, BL
    REDDY, MA
    KAHN, DR
    ANNALS OF THORACIC SURGERY, 1994, 57 (03): : 691 - 696
  • [35] SILICONE SENSITIZATION IN PATIENTS WITH END-STAGE RENAL-DISEASE
    ACCHIARDO, SR
    SMALLEY, DL
    SHAKLIN, DR
    BURK, L
    SMITH, SJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 430 - 430
  • [36] NITRENDIPINE IN PATIENTS WITH END-STAGE RENAL-DISEASE AND HYPERTENSION
    BAMBAUER, R
    JUTZLER, GA
    WEBER, U
    WALTER, R
    KELLER, HE
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 : S133 - S135
  • [37] EXERCISE TOLERANCE OF END-STAGE RENAL-DISEASE PATIENTS
    SAGIV, M
    RUDOY, J
    ROTSTEIN, A
    FISHER, N
    BENARI, J
    NEPHRON, 1991, 57 (04): : 424 - 427
  • [38] THE QUALITY OF LIFE OF PATIENTS WITH END-STAGE RENAL-DISEASE
    EVANS, RW
    MANNINEN, DL
    GARRISON, LP
    HART, LG
    BLAGG, CR
    GUTMAN, RA
    HULL, AR
    LOWRIE, EG
    NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (09): : 553 - 559
  • [39] CALCIPHYLAXIS IN 3 PATIENTS WITH END-STAGE RENAL-DISEASE
    IVKER, RA
    WOOSLEY, J
    BRIGGAMAN, RA
    ARCHIVES OF DERMATOLOGY, 1995, 131 (01) : 63 - 68
  • [40] BIOAVAILABILITY OF LABETALOL IN PATIENTS WITH END-STAGE RENAL-DISEASE
    LUKE, DR
    AWNI, WM
    HALSTENSON, CE
    OPSAHL, JA
    MATZKE, GR
    THERAPEUTIC DRUG MONITORING, 1992, 14 (03) : 203 - 208